Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Aytu Biopharma Inc (AYTU)

Aytu Biopharma Inc (AYTU)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 11,167
  • Shares Outstanding, K 38,575
  • Annual Sales, $ 65,630 K
  • Annual Income, $ -58,290 K
  • 60-Month Beta -0.42
  • Price/Sales 0.08
  • Price/Cash Flow N/A
  • Price/Book 0.16
Trade AYTU with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.71
  • Most Recent Earnings -0.27 on 05/16/22
  • Next Earnings Date 09/26/22
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 442.43% ( +40.88%)
  • Historical Volatility 211.20%
  • IV Percentile 85%
  • IV Rank 38.69%
  • IV High 1,021.18% on 08/01/22
  • IV Low 77.16% on 09/14/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 27
  • Volume Avg (30-Day) 28
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 2,815
  • Open Int (30-Day) 3,183

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.24
  • Number of Estimates 1
  • High Estimate -0.24
  • Low Estimate -0.24
  • Prior Year -0.67
  • Growth Rate Est. (year over year) +64.18%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2700 +9.00%
on 08/10/22
0.6567 -55.19%
on 07/19/22
-0.3043 (-50.84%)
since 07/15/22
3-Month
0.2700 +9.00%
on 08/10/22
0.8097 -63.65%
on 07/01/22
-0.2219 (-42.99%)
since 05/13/22
52-Week
0.2700 +9.00%
on 08/10/22
3.8900 -92.43%
on 09/02/21
-3.1657 (-91.49%)
since 08/13/21

Most Recent Stories

More News
Aytu BioPharma to Participate in the Canaccord Genuity 42nd Annual Growth Conference

ENGLEWOOD, CO / ACCESSWIRE / July 26, 2022 / Aytu BioPharma, Inc. (the "Company") (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that...

AYTU : 0.2943 (+1.66%)
Aytu BioPharma Announces Initiation of the AR101 PREVEnt Trial for the Treatment of Vascular Ehlers-Danlos Syndrome

ENGLEWOOD, CO / ACCESSWIRE / July 20, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the initiation of...

AYTU : 0.2943 (+1.66%)
Aytu BioPharma Announces the Appointment of Vivian Liu to the Company's Board of Directors

ENGLEWOOD, CO / ACCESSWIRE / June 29, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the appointment of...

AYTU : 0.2943 (+1.66%)
Aytu BioPharma to Participate in the Lytham Partners Summer 2022 Investor Conference

ENGLEWOOD, CO / ACCESSWIRE / June 13, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that the company...

AYTU : 0.2943 (+1.66%)
Aytu BioPharma Reports Third Quarter 2022 Financial Results and Outlines Key Strategic Priorities

Quarterly Net Revenue Increased 79% Year-Over-Year to $24.2 Million, the Highest Revenue in Company History Strategic Priorities Focused on Driving Revenue Growth, Increasing Financial Efficiencies and...

AYTU : 0.2943 (+1.66%)
Aytu BioPharma Announces Positive Preclinical Data in Ventilator-Associated Pneumonia with its Novel, Proprietary Healight(TM) Delivery Technology

Preclinical Proof-of-Concept Study Demonstrates Effectiveness of Healight in Delaying Time to Development of Ventilator-Associated Pneumonia ENGLEWOOD, CO / ACCESSWIRE / April 25, 2022 / Aytu BioPharma,...

AYTU : 0.2943 (+1.66%)
Aytu BioPharma Announces Fast Track Designation Granted to AR101 for the Treatment of Vascular Ehlers-Danlos Syndrome

ENGLEWOOD, CO / ACCESSWIRE / April 19, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that the U.S. Food...

AYTU : 0.2943 (+1.66%)
Aytu BioPharma Announces FDA Orange Book Listing of Newly Issued Patent for Cotempla XR-ODT(R)

ENGLEWOOD, CO / ACCESSWIRE / March 23, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that its newly issued...

AYTU : 0.2943 (+1.66%)
Aytu BioPharma to Participate in the Cantor Fitzgerald Virtual Rare Orphan Disease Summit

ENGLEWOOD, CO / ACCESSWIRE / March 22, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that management...

AYTU : 0.2943 (+1.66%)
Aytu BioPharma to Participate in the 34th Annual Roth Conference

ENGLEWOOD, CO / ACCESSWIRE / March 8, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that Mark Oki, chief...

AYTU : 0.2943 (+1.66%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Aytu BioScience, Inc. is a healthcare company which focused on commercialization of novel products in the field of urology. The company's marketed products consists of ProstaScint(R), Primsol(R) and MiOXSYS(TM) which addresses prostate cancer, urinary tract infections, male infertility and male sexual...

See More

Key Turning Points

3rd Resistance Point 0.3087
2nd Resistance Point 0.3012
1st Resistance Point 0.2953
Last Price 0.2943
1st Support Level 0.2819
2nd Support Level 0.2744
3rd Support Level 0.2685

See More

52-Week High 3.8900
Fibonacci 61.8% 2.5072
Fibonacci 50% 2.0800
Fibonacci 38.2% 1.6528
Last Price 0.2943
52-Week Low 0.2700

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar